glp-1 covered by medicare Drug Coverage Nearly Four Million Medicare Beneficiaries

Retatrutide may be the preferred option for patients with specific, co-existing metabolic issues, such as significant non-alcoholic fatty liver disease (MASH) , or for those who need to maximize weight loss results

In 2 retrospective cohort studies from Europe, GLP-1 RA use was associated with slower progression to the composite major adverse liver outcome (ie, cirrhosis, decompensated cirrhosis, HCC, liver-related death)

Insulin- and lipopolysaccharide-mediated signaling in adipose tissue macrophages regulates postprandial glycemia through Akt-mTOR activation

Published July 13, 2022

For comorbid metabolic diseases, such as diabetes and obesity, the use of GLP-1RAs generally does not increase cancer risk and may offer certain benefits

The first glucagon/GLP-1 receptor co-agonist was discovered and validated in preclinical models in 2009